GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Cash Ratio

Lannett Co (Lannett Co) Cash Ratio : 0.06 (As of Mar. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Lannett Co's Cash Ratio for the quarter that ended in Mar. 2023 was 0.06.

Lannett Co has a Cash Ratio of 0.06. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Lannett Co's Cash Ratio or its related term are showing as below:

LCINQ' s Cash Ratio Range Over the Past 10 Years
Min: 0.06   Med: 0.82   Max: 6.45
Current: 0.06

During the past 13 years, Lannett Co's highest Cash Ratio was 6.45. The lowest was 0.06. And the median was 0.82.

LCINQ's Cash Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.58 vs LCINQ: 0.06

Lannett Co Cash Ratio Historical Data

The historical data trend for Lannett Co's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Cash Ratio Chart

Lannett Co Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.79 0.67 1.03 0.84

Lannett Co Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 0.84 0.71 0.50 0.06

Competitive Comparison of Lannett Co's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lannett Co's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Lannett Co's Cash Ratio falls into.



Lannett Co Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Lannett Co's Cash Ratio for the fiscal year that ended in Jun. 2022 is calculated as:

Cash Ratio (A: Jun. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=87.854/104.94
=0.84

Lannett Co's Cash Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash Ratio (Q: Mar. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=46.54/733.079
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lannett Co  (OTCPK:LCINQ) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Lannett Co Cash Ratio Related Terms

Thank you for viewing the detailed overview of Lannett Co's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lannett Co (Lannett Co) Business Description

Traded in Other Exchanges
N/A
Address
1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Executives
John C Chapman director 9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew officer: Chief Executive Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber officer: Secretary
Samuel H Israel officer: Chief Legal Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt officer: Vice President of Quality 9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski officer: Chief Operating Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik director 9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira director 9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa director 9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith other: Vice President
Maureen Cavanaugh officer: Senior Vice President and CCOO 9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber officer: Treasurer
Arthur P Bedrosian officer: President P O BOX D 1400, POMONA NY 10970